MX2017007374A - Combinacion de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anti-cancer con un derivado de quinazolina. - Google Patents

Combinacion de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anti-cancer con un derivado de quinazolina.

Info

Publication number
MX2017007374A
MX2017007374A MX2017007374A MX2017007374A MX2017007374A MX 2017007374 A MX2017007374 A MX 2017007374A MX 2017007374 A MX2017007374 A MX 2017007374A MX 2017007374 A MX2017007374 A MX 2017007374A MX 2017007374 A MX2017007374 A MX 2017007374A
Authority
MX
Mexico
Prior art keywords
derivative
dihydro
oxo
combination
cancer activity
Prior art date
Application number
MX2017007374A
Other languages
English (en)
Inventor
Bladt Friedhelm
FRIESE-HAMIN Manja
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52133766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017007374(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2017007374A publication Critical patent/MX2017007374A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición farmacéutica de 3-(1-{3-[5-(1-metil-piperidin-4-il metoxi)-pirimidin-2-il]-bencil}-6-oxo-1,6-dihidro-piridazin-3-il) -benzonitrilo o una sal y/o solvato farmacéuticamente aceptable del mismo en combinación con amida del ácido 4-[(S)-2-azetidin-1-i l-1-(4-cloro-3-trifluorometil-fenil)-etilamino]-quinazolin-8-carb oxílico.
MX2017007374A 2014-12-11 2015-11-12 Combinacion de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anti-cancer con un derivado de quinazolina. MX2017007374A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14004186 2014-12-11
PCT/EP2015/002266 WO2016091347A1 (en) 2014-12-11 2015-11-12 Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative

Publications (1)

Publication Number Publication Date
MX2017007374A true MX2017007374A (es) 2017-11-06

Family

ID=52133766

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007374A MX2017007374A (es) 2014-12-11 2015-11-12 Combinacion de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anti-cancer con un derivado de quinazolina.

Country Status (19)

Country Link
US (1) US10231972B2 (es)
EP (1) EP3229796B1 (es)
JP (1) JP6791855B2 (es)
KR (1) KR20170090498A (es)
CN (1) CN106999492B (es)
AU (1) AU2015360006B2 (es)
BR (1) BR112017010232A2 (es)
CA (1) CA2970394C (es)
CL (1) CL2017001477A1 (es)
ES (1) ES2945865T3 (es)
IL (1) IL252750B (es)
MX (1) MX2017007374A (es)
NZ (1) NZ731770A (es)
PH (1) PH12017500719A1 (es)
RU (1) RU2704120C2 (es)
SG (1) SG11201704763SA (es)
UA (1) UA120106C2 (es)
WO (1) WO2016091347A1 (es)
ZA (1) ZA201704621B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311812B (zh) * 2016-10-27 2020-03-17 福建广生堂药业股份有限公司 作为c-MET抑制剂的吡啶酮类化合物
WO2022101459A1 (en) * 2020-11-16 2022-05-19 Merck Patent Gmbh Kinase inhibitor combinations for cancer treatment
EP4346829A1 (en) 2021-06-04 2024-04-10 Merck Patent GmbH Compounds for the treatment of glioblastoma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005057924A1 (de) * 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
EA015754B1 (ru) * 2005-12-21 2011-12-30 Янссен Фармацевтика, Н.В. Триазолопиридазины в качестве модуляторов тирозинкиназы
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
WO2010120599A2 (en) * 2009-04-16 2010-10-21 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
MX355325B (es) * 2010-11-24 2018-04-16 Merck Patent Gmbh Quinazolincarboxamida azetidinas.
US20150044211A1 (en) * 2012-03-19 2015-02-12 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds
JP2014034534A (ja) * 2012-08-08 2014-02-24 Nippon Kayaku Co Ltd ＨＳＰ９０阻害剤とｍＴＯＲ阻害剤の組み合わせ
AU2013329865B2 (en) * 2012-10-11 2018-04-26 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a MEK inhibitor

Also Published As

Publication number Publication date
US20170340635A1 (en) 2017-11-30
NZ731770A (en) 2023-05-26
US10231972B2 (en) 2019-03-19
IL252750A0 (en) 2017-08-31
JP6791855B2 (ja) 2020-11-25
UA120106C2 (uk) 2019-10-10
RU2017124371A3 (es) 2019-06-04
WO2016091347A1 (en) 2016-06-16
JP2018502842A (ja) 2018-02-01
RU2704120C2 (ru) 2019-10-24
EP3229796A1 (en) 2017-10-18
IL252750B (en) 2020-11-30
RU2017124371A (ru) 2019-01-11
KR20170090498A (ko) 2017-08-07
ES2945865T3 (es) 2023-07-10
CA2970394A1 (en) 2016-06-16
CN106999492A (zh) 2017-08-01
CL2017001477A1 (es) 2018-01-05
AU2015360006A1 (en) 2017-07-27
EP3229796B1 (en) 2023-03-01
ZA201704621B (en) 2021-05-26
PH12017500719A1 (en) 2017-10-09
CA2970394C (en) 2023-03-14
CN106999492B (zh) 2020-12-11
SG11201704763SA (en) 2017-07-28
BR112017010232A2 (pt) 2018-01-02
AU2015360006B2 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
MX2016012021A (es) Compuestos heterociclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
EA201891142A1 (ru) Контроль клеточных окислительно-восстановительных уровней
EP3181559A4 (en) 2-(2,4,5-substituted aniline) pyrimidine derivative, pharmaceutical composition and use thereof
MX2022001655A (es) Dispersiones solidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc).
IL268690A (en) (4)- 1-(1-(S-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(1-methyl-H1-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridine-2 (H1)-Onat salts and their crystalline structures and pharmaceutical preparations containing them
ZA201804387B (en) Pharmaceutical composition containing 2-{4-[n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide
PH12017500719A1 (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative
MX2016003754A (es) Una composicion farmaceutica estable que contiene amlodipina y valsartan.
WO2015031598A3 (en) Therapeutic dnp derivatives and methods using same
PH12017502252B1 (en) Stable pharmaceutical composition for oral administration
PH12017500718A1 (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an egfr inhibitor
MX359110B (es) Combinacion de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anticancer con un inhibidor de mek.
PH12016500948A1 (en) Combination of a 6-oxo- 1,6-dihydro-pyridazine derivate having anti-cancer activity with gefitinib
LT3408260T (lt) Kristalinė (2s,4r)-5-(5'-chlor-2-fluor-[1,1'-bifenil]-4-il)-2-(etoksimetil)-4-(3-hidroksi-izoksazol-5-karboksamido)-2-metilpentanoinė rūgštis ir jos panaudojimai
EP3150587A4 (en) Deuterium substituted 1-[2-(2,4-dimethyl-thiophenyl)-phenyl]piperazine compound or derivative thereof, and pharmaceutical composition and use thereof
BR112018074162A2 (pt) composições farmacêuticas adequadas para administração oral e administração parenteral, métodos para prevenir ou tratar infecção fúngica em um indivíduo humano ou animal e para produzir uma composição farmacêutica, e, uso de uma composição farmacêutica.
MX2017013788A (es) Composicion farmaceutica estabilizada.
HRP20171295T1 (hr) Derivat 6-okso-1,6-dihidro-piridazina za upotrebu za liječenje hepatocelularnog karcinoma (hcc)
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
MX2022000358A (es) Preparacion farmaceutica.
PH12016500964A1 (en) A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (rcc)
ალექსანდრე ჩხიტაური Theoretical aspects of financial control legal regulation mechanisms
MX2017008497A (es) Nuevos compuestos heterocíclicos y su uso tanto en medicina como en cosmética.
UA98919U (ru) 4-этил-3-(феноксиметил)-5-((2-((5-феноксиметил)-4-фенил-4н-1,2,4-триазол-3-ил)тио)этил)тио)-4н-1,2,4-триазол, проявляющая диуретическую активность
TH1601002081A (th) รูปแบบเภสัชภัณฑ์ซึ่งประกอบรวมด้วยโซเดียม 1-[6-(มอร์โฟลิน-4-อิล)ไพริมิดิน-4- อิล]-4-(1h-1,2,3-ไตรอะโซล-1-อิล)-1h-ไพราโซล-5-โอเลต

Legal Events

Date Code Title Description
FG Grant or registration